Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Fig. 6

On treatment monitoring of circulating B lymphocyte differentiation status and Ig levels. a Circulating B lymphocyte differentiation status for each Bm population before and during treatment. Effect of response groups and time points, and their interaction were assessed with a one-way ANOVA group comparison using a linear mixed effects models for repeated measures; between indicated groups, *: p < 0.05; **: p < 0.01. b Evaluations of total circulating levels of IgG (top), IgA (middle) and IgM (bottom). A one-way ANOVA group comparison using a linear mixed effects models for repeated measures statistical analysis reveals that all groups had statistical variations in time for IgG; ***: p < 0.001

Back to article page